Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer
IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs...
Cancer
US Digestive Health Celebrates the Grand Opening of Relocated Office
The state-of-the-art practice will employ some of the region’s most-experienced gastroenterology doctors and physicians Ribbon Cutting USDH staff members gather...
Biomea Fusion To Participate In Upcoming Investor Events
REDWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a biopharmaceutical company focused on...
Medical City Frisco is the Latest Hospital to Utilize Surgalign’s HOLO Portal Surgical Guidance System
This represents the first site in Texas; Medical City Frisco to leverage the benefits of HOLO Portal, the world’s first...
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering...
Orion Corporation: Managers’ transactions – Jari Karlson
ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2023 at 15.00 EET Orion Corporation: Managers’ transactions – Jari Karlson Orion Corporation...
Orion Corporation: Managers’ transactions – Olli Huotari
ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2023 at 15.00 EET Orion Corporation: Managers’ transactions – Olli Huotari Orion Corporation...
Orion Corporation: Managers’ transactions – Satu Ahomäki
ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2023 at 15.00 EET Orion Corporation: Managers’ transactions – Satu Ahomäki Orion Corporation...
Orion Corporation: Managers’ transactions – Juhani Kankaanpää
ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2023 at 15.00 EET Orion Corporation: Managers’ transactions – Juhani Kankaanpää Orion Corporation...
Orion Corporation: Managers’ transactions – Virve Laitinen
ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2023 at 15.00 EET Orion Corporation: Managers’ transactions – Virve Laitinen Orion Corporation...
Orion Corporation: Managers’ transactions – Niclas Lindstedt
ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2023 at 15.00 EET Orion Corporation: Managers’ transactions – Niclas Lindstedt Orion Corporation...
Orion Corporation: Managers’ transactions – Hao Pan
ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2023 at 15.00 EET Orion Corporation: Managers’ transactions – Hao Pan Orion Corporation...
Orion Corporation: Managers’ transactions – Outi Vaarala
ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MARCH 2023 at 15.00 EET Orion Corporation: Managers’ transactions – Outi Vaarala Orion Corporation...
AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients
Ongoing efforts to open additional clinical sites for recruitment at premier cancer centers across the U.S. and Europe are in...
ABVC BioPharma Provides 2023 Pipeline Update
FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
Research illustrates company’s progress in working to end the diagnostic odyssey and includes data with implications for how care is...
Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission
Robust enrollment of up to 5 patients per month continues in ongoing Phase 1b/2a next-generation CAR-T NXC-201 clinical trial in...
Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
HAMILTON, BERMUDA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Altamira’s ability to target different KRAS mutations with a single polyvalent siRNA...
Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission
Robust enrollment of up to 5 patients per month continues in ongoing Phase 1b/2a next-generation CAR-T NXC-201 clinical trial in...
IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer
The study will be partially funded by Break Through Cancer through the Ovarian Minimal Residual Disease Team Lab LAWRENCEVILLE, NJ...